Találati lista | Tudóstér

001-es BibID:	BIBFORM001053
035-os BibID:	(scopus)34447298092 (wos)000248154300017
Első szerző:	Barok Márk (biofizikus)
Cím:	Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance / Barok M., Isola J., Pályi-Krekk Zs., Nagy P., Juhász I., Vereb Gy., Kauraniemi P., Kapanen A., Tanner M., Vereb Gy., Szöllősi J.
Dátum:	2007
Megjegyzések:	Trastuzumab is a recombinant antibody drug that is widely used for the treatment of breast cancer. Despite encouraging clinical results, some cancers are primarily resistant to trastuzumab, and a majority of those initially responding become resistant during prolonged treatment. The mechanisms of trastuzumab resistance have not been fully understood. We examined the role of antibody-dependent cellular cytotoxicity (ADCC) using JIMT-1 cells that are ErbB2 positive but intrinsically resistant to trastuzumab in vitro. Unexpectedly, in experiments mimicking adjuvant therapy of submacroscopic disease in vivo (JIMT-1 cells inoculated s.c. in severe combined immunodeficiency mice), trastuzumab was able to inhibit the outgrowth of macroscopically detectable xenograft tumors for up to 5-7 weeks. The effect is likely to be mediated via ADCC because trastuzumab-F(ab')(2) was ineffective in this model. Moreover, in vitro ADCC reaction of human leukocytes was equally strong against breast cancer cells intrinsically sensitive (SKBR-3) or resistant (JIMT-1) to trastuzumab or even against a subline of JIMT-1 that was established from xenograft tumors growing despite trastuzumab treatment. These results suggest that ADCC may be the predominant mechanism of trastuzumab action on submacroscopic tumor spread. Thus, measuring the ADCC activity of patient's leukocytes against the tumor cells may be a relevant predictor of clinical trastuzumab responsiveness in vivo.
Tárgyszavak:	Orvostudományok Természettudományok Elméleti orvostudományok Biológiai tudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk ErbB2 receptor trastuzumab breast cancer antibody therapy
Megjelenés:	Molecular Cancer Therapeutics. - 6 : 7 (2007), p. 2065-2072. -
További szerzők:	Isola, Jorma Pályiné Krekk Zsuzsanna (1974-) (molekuláris biológus) Nagy Péter (1971-) (biofizikus) Juhász István (1956-) (bőrgyógyász, bőrsebész, kozmetológus, klinikai onkológus) Vereb György (1938-) (biokémikus, sejtbiológus) Kauraniemi, Päivikki Kapanen, Anita I. Tanner, Minna Vereb György (1965-) (biofizikus, orvos) Szöllősi János (1953-) (biofizikus)
Internet cím:	elektronikus változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM002283
Első szerző:	Márkász László (gyermekgyógyász)
Cím:	Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells / Márkász László, Stuber György, Vanherberghen Bruno, Flaberg Emilie, Oláh Éva, Carbone Ennio, Eksborg Staffan, Klein Éva, Skribek Henriette, Székely László
Dátum:	2007
Megjegyzések:	Tumors are considered to be possible targets of immunotherapy using stimulated and expanded autologous or allogeneic natural killer (NK) cellsmis matched for MHC class I molecules and inhibitory NK receptors. NK cells based immunoadjuvant therapies are carried out in combination with standard chemotherapeutic protocols. In the presented study, we characterized the effect of 28 frequently used chemotherapeutic agents on the capacity of NK cellsto kill target cells. We found that treatment of NK cellswith the drugsvinblas tine, paclitaxel, docetaxel, cladribine, chlorambucil, bortezomib, and MG-132 effectively inhibited NK cells-mediated killing without affecting the viability of NK cells. On the other hand, the following drugspermitted efficient NK cells-mediated killing even at concentrationsco mparable with or higher than the maximally achieved therapeutic concentration in vivo in humans: asparaginase, bevacizumab, bleomycin, doxorubicin, epirubicin, etoposide, 5-fluorouracil, hydroxyurea, streptozocin, and 6-mercaptopurine.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban natural killer cells cytotoxic activity chemotherapeutic drugs
Megjelenés:	Molecular Cancer Therapeutics. - 6 : 2 (2007), p. 644-654. -
További szerzők:	Stuber György Vanherberghen, Bruno Flaberg, Emilie Carbone Ennio Eksborg, Staffan Klein Éva Skribek, Henriette Székely László Oláh Éva (1943-2019) (gyermekgyógyász, klinikai genetikus)
Internet cím:	elektronikus változat elektronikus változat DOI
Borító:
Saját polcon: